Immunocore will present Phase 1 data for brenetafusp plus KIMMTRAK® (tebentafusp-tebn) in metastatic uveal melanoma, during a late-breaking oral session at the 2026 SITC meeting
Immunocore will present Phase 1 data for brenetafusp alone and in combination with KIMMTRAK in HLA-A*02:01-positive metastatic uveal melanoma at the 2026 SITC Annual Meeting. The company describes the program as the first combination of two T cell engagers in a solid tumor, with a poster on November 6 and a late-breaking oral presentation on November 7.
Key figures
- Drug Name
- brenetafusp (IMC-F106C) plus KIMMTRAK (tebentafusp-tebn)
- Phase Of Trial
- Phase 1/2
- Trial
- IMC-F106C-101
- Indication
- metastatic uveal melanoma
- Abstract number
- 1177
- Presentation dates
- ["2026-11-06 poster","2026-11-07 oral late-breaking session"]
AI analysis
Red flags1 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.